CureVac disappoints in COVID vaccine trial
Nature Podcast
English - June 18, 2021 20:13 - 13 minutes - 18.5 MB - ★★★★★ - 672 ratingsScience Technology Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Communities, COVID and credit: the state of science collaborations
Next Episode: Quantum compass might help birds 'see' magnetic fields
After a slew of wildly successful vaccine trials, this week marked a more underwhelming result. The third mRNA vaccine to complete phase three trials, developed by CureVac, is just 47% effective at staving off disease according to preliminary data. This is a stark contrast with previous mRNA vaccines from Moderna and Pfizer BioNtec which returned around twice that efficacy in their trials. In this episode of Coronapod, we ask why the CureVac vaccine has faltered, and what this might mean for the future of the pandemic and mRNA vaccine development.
News: CureVac COVID vaccine let-down spotlights mRNA design challenges
News Feature: How COVID unlocked the power of RNA vaccines
Hosted on Acast. See acast.com/privacy for more information.